The heart–joints connection: atherosclerosis and inflammation

References

• Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb.14, 840–856 (1994).
   PubMed Web of Science ®Google Scholar
• Frostegard J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis145, 33–43 (1999).
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med.353, 46–57 (2005).
   PubMed Web of Science ®Google Scholar
• Szalai AJ, Alarcón GS, Calvo-Alén J et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatol.44, 864–868 (2005).
   PubMed Web of Science ®Google Scholar
• del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum.44, 2737–2745 (2001).
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler. Thromb. Vasc. Biol.24, 1309–1314 (2004).
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc. Natl Acad. Sci. USA86, 1046–1050 (1989).
   PubMed Web of Science ®Google Scholar
• Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis DOI: 16982059 (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Orosz Z, Csiszar A, Labinskyy N et al. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD(P)H oxidase activation. Am. J. Physiol. Heart Circ. Physiol.292, H130–H139 (2007).
   PubMed Web of Science ®Google Scholar
• Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol.19, 1623–1629 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res.84, 489–497 (1999).
   PubMed Web of Science ®Google Scholar
• Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J. Thromb. Haemost.3, 1646–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Espinola-Klein C, Rupprecht HJ, Blankenberg S et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke33, 2581–2586 (2002).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kishi M, Atsumi T et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J. Lipid Res.44, 716–726 (2003).
   PubMed Web of Science ®Google Scholar
• Huang Y, Jaffa A, Koskinen S, Takei A, Lopes-Virella MF. Oxidized LDL-containing immune complexes induce Fc γ receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler. Thromb. Vasc. Biol.19, 1600–1607 (1999).
   PubMedGoogle Scholar
• Hoymans VY, Bosmans JM, Van Herck PL, Ieven MM, Vrints CJ. Implications of antibodies to heat-shock proteins in ischemic heart disease. Int. J. Cardiol. DOI: 17383754 (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Jantos CA, Krombach C, Wuppermann FN et al. Antibody response to the 60-kDa heat-shock protein of Chlamydia pneumoniae in patients with coronary artery disease. J. Infect. Dis.181, 1700–1705 (2000).
   PubMedGoogle Scholar
• Xiao Q, Mandal K, Schett G et al. Association of serum-soluble heat shock protein 60 with carotid atherosclerosis: clinical significance determined in a follow-up study. Stroke36, 2571–2576 (2005).
   PubMed Web of Science ®Google Scholar
• Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol.20, 2094–2099 (2000).
   PubMed Web of Science ®Google Scholar
• Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J.321, 199–204 (2000).
   PubMed Web of Science ®Google Scholar
• Springer TA. Adhesion receptors of the immune system. Nature346, 425–434 (1990).
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett.286, 152–154 (1991).
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Hama S et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation105, 290–292 (2002).
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest.96, 2758–2767 (1995).
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Hama S et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation108, 2751–2756 (2003).
   PubMed Web of Science ®Google Scholar
• McMahon M, Grossman J, Fitzgerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum.54, 2541–2549 (2006).
   PubMed Web of Science ®Google Scholar
• Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N. Engl. J. Med.249, 553–556 (1953).
   PubMed Web of Science ®Google Scholar
• Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheum.13, 125–128 (1970).
   PubMed Web of Science ®Google Scholar
• Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J. Rheumatol.24, 445–451 (1997).
   PubMed Web of Science ®Google Scholar
• Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann. Rheum. Dis.64, 1595–1601 (2005).
   PubMed Web of Science ®Google Scholar
• Nicola PJ, Crowson CS, Maradit-Kremers H et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum.54, 60–67 (2006).
   PubMed Web of Science ®Google Scholar
• Nicola PJ, Maradit-Kremers H, Roger VL et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum.52, 412–420 (2005).
   PubMed Web of Science ®Google Scholar
• Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation103, 2055–2059 (2001).
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann. Rheum. Dis.66, 76–80 (2007).
   PubMedGoogle Scholar
• Gabriel SE, Crowson CS, Kremers HM et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum.48, 54–58 (2003).
   PubMed Web of Science ®Google Scholar
• Kroot EJ, van Leeuwen MA, van Rijswijk MH et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann. Rheum. Dis.59, 954–958 (2000).
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Crowson CS, Nicola PJ et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum.52, 402–411 (2005).
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum.52, 722–732 (2005).
   PubMed Web of Science ®Google Scholar
• Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann. Rheum. Dis.66, 70–75 (2007).
   PubMedGoogle Scholar
• Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation107, 1303–1307 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am. J. Cardiol.59, G91–G94 (1987).
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation97, 1837–1847 (1998).
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Avalos I et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res. Ther.8, R186 (2006).
   PubMed Web of Science ®Google Scholar
• Dessein PH, Joffe BI, Veller MG et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol.32, 435–442 (2005).
   PubMed Web of Science ®Google Scholar
• Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol.33, 2425–2432 (2006).
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Solus JF et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis DOI: 17266963 (2007) (Epub ahead of print).
   Google Scholar
• Holme I, Enger SC, Helgeland A et al. Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries. Statistical analysis from the Oslo study. Arteriosclerosis1, 250–256 (1981).
   PubMedGoogle Scholar
• Young W, Gofman JW, Tandy R, Malamud N, Waters ES. The quantitation of atherosclerosis. II. Quantitative aspects of the relationship of blood pressure and atherosclerosis. Am. J. Cardiol.6, 294–299 (1960).
   PubMedGoogle Scholar
• Adams MR, Nakagomi A, Keech A et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation92, 2127–2134 (1995).
   PubMed Web of Science ®Google Scholar
• Iglesias del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JC. Carotid intima-media thickness at different sites: relation to incident myocardial infraction. Eur. Heart J.23, 934–940 (2002).
   PubMed Web of Science ®Google Scholar
• Roman MJ, Moeller E, Davis A et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann. Intern. Med.144, 249–256 (2006).
   PubMed Web of Science ®Google Scholar
• Grover S, Sinha RP, Singh U, Tewari S, Aggarwal A, Misra R. Subclinical atherosclerosis in rheumatoid arthritis in India. J. Rheumatol.33, 244–247 (2006).
   PubMedGoogle Scholar
• Kumeda Y, Inaba M, Goto H et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum.46, 1489–1497 (2002).
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Polychuck I, Szendro G et al. Duplex study of the carotid and femoral arteries of patients with rheumatoid arthritis: a controlled study. Semin. Arthritis Rheum.35, 18–23 (2005).
   PubMedGoogle Scholar
• Pahor A, Hojs R, Gorenjak M, Rozman B. Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol. Int.27, 119–123 (2006).
   PubMed Web of Science ®Google Scholar
• Park YB, Ahn CW, Choi HK et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum.46, 1714–1719 (2002).
   PubMedGoogle Scholar
• del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum.48, 1833–1840 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J. Rheumatol.32, 1219–1223 (2005).
   PubMed Web of Science ®Google Scholar
• del Rincon I, Freeman GL, Haas RW, O’Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum.52, 3413–3423 (2005).
   PubMed Web of Science ®Google Scholar
• del Rincon I, O’Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis DOI: 17097659 (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of Type 2 diabetes and/or cardiovascular disease? Diabetes Care27, 2676–2681 (2004).
   PubMed Web of Science ®Google Scholar
• Pamuk ON, Unlu E, Cakir N. Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis. J. Rheumatol.33, 2447–2452 (2006).
   PubMedGoogle Scholar
• Henrichot E, Juge-Aubry CE, Pernin A et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler. Thromb. Vasc. Biol.25, 2594–2599 (2005).
   PubMed Web of Science ®Google Scholar
• Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxf.)42, 292–297 (2003).
   PubMedGoogle Scholar
• Vaudo G, Marchesi S, Gerli R et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis.63, 31–35 (2004).
   PubMed Web of Science ®Google Scholar
• Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum.48, 72–80 (2003).
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Raggi P et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum.52, 3045–3053 (2005).
   PubMed Web of Science ®Google Scholar
• Sacks JJ, Helmick CG, Langmaid G, Sniezek JE. Trends in deaths from systemic lupus erythematosus – United States, 1979–1998. MMWR Morb. Mortal. Wkly Rep.51, 371–374 (2002).
   PubMedGoogle Scholar
• Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J. Rheumatol.31, 713–719 (2004).
   PubMed Web of Science ®Google Scholar
• Aravanis C, Toutouzas P, Yatzidis I. Fatal myocardial infarction in lupus erythematosus. Report of a case of a young female patient. Vasc. Dis.1, 258–260 (1964).
   PubMedGoogle Scholar
• Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med.60, 221–225 (1976).
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J. Rheumatol.22, 1259–1264 (1995).
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum.54, 2550–2557 (2006).
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol.145, 408–415 (1997).
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimbürger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation104, 1887–1893 (2001).
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus. The Toronto Risk Factor Study. Arthritis Rheum.48, 3159–3167 (2003).
   PubMed Web of Science ®Google Scholar
• Toloza SMA, Uribe AG, McGwin G Jr et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXIII: baseline predictors of vascular events. Arthritis Rheum.50, 3947–3957 (2004).
   PubMed Web of Science ®Google Scholar
• Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J. Rheumatol.26, 2363–2368 (1999).
   PubMed Web of Science ®Google Scholar
• Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum.42, 51–60 (1999).
   PubMed Web of Science ®Google Scholar
• Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Balt.)71, 291–302 (1992).
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum.44, 2331–2337 (2001).
   PubMed Web of Science ®Google Scholar
• Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis.62, 1071–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald SG et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum.50, 151–159 (2004).
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Oeser A, Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med.349, 2407–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J. Rheumatol.33, 2458–2463 (2006).
   PubMed Web of Science ®Google Scholar
• Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JPA, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxf.)42, 645–651 (2003).
   PubMed Web of Science ®Google Scholar
• Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thrombosis Res.114, 593–595 (2004).
   PubMed Web of Science ®Google Scholar
• Von Feldt JM, Scalzi LV, Cucchiara AJ et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum.54, 2220–2227 (2006).
   PubMed Web of Science ®Google Scholar
• Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation99, 2192–2217 (1999).
   PubMed Web of Science ®Google Scholar
• Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet359, 1173–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum.55, 531–536 (2006).
   PubMed Web of Science ®Google Scholar
• van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res. Ther.8, R151 (2006).
   PubMed Web of Science ®Google Scholar
• Davis JM, III, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J. Rheumatol.32, 1856–1862 (2005).
   PubMed Web of Science ®Google Scholar
• Del Rincon I, O’Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum.50, 3813–3822 (2004).
   PubMed Web of Science ®Google Scholar
• Davis JM, III, Maradit KH, Crowson CS et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum.56, 820–830 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am. J. Med.89, 322–326 (1990).
   PubMed Web of Science ®Google Scholar
• Rustan AC, Nossen JO, Tefre T, Drevon CA. Inhibition of very low density lipoprotein secretion by chloroquine, verapamil and monensin takes place in the Golgi complex. Biochim. Biophys. Acta930, 311–319 (1987).
   PubMedGoogle Scholar
• Chen HW, Leonard DA. Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells. J. Biol. Chem.259, 8156–8162 (1984).
   PubMed Web of Science ®Google Scholar
• Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus1, S16–S22 (1996).
   Google Scholar
• Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J. Rheumatol.26, 325–330 (1999).
   PubMed Web of Science ®Google Scholar
• Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann. Rheum. Dis.56, 374–377 (1997).
   PubMed Web of Science ®Google Scholar
• Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation106, 2184–2187 (2002).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum.51, 447–450 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol.32, 1213–1218 (2005).
   PubMed Web of Science ®Google Scholar
• Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol.86, 123–130 (2002).
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med.349, 2399–23406 (2003).
   PubMed Web of Science ®Google Scholar
• Hermann F, Forster A, Chenevard R et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J. Am. Coll. Cardiol.45, 461–464 (2005).
   PubMed Web of Science ®Google Scholar
• Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzáalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus12, 607–611 (2003).
   PubMed Web of Science ®Google Scholar
• McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet363, 2015–2021 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez M, McGwin G Jr, Andrade RM et al. Systemic lupus erythematosus in a multiethnic US cohort, LUMINA: a pilot or preliminary evaluation of the impact of statins in disease activity. J. Clin. Rheumatol. (2007) (In Press).
   Google Scholar
• White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am. J. Cardiol.99, 91–98 (2007).
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J. Am. Med. Assoc.296, 1633–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet368, 1771–1781 (2006).
   PubMed Web of Science ®Google Scholar
• van dM I, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch. Intern. Med.163, 1323–1328 (2003).
   PubMedGoogle Scholar
• Andrade RM, Alarcon GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatol.1, 225–233 (2006).
   Google Scholar
• Al-Herz A, Ensworth S, Shojania K, Esdaile JM. Cardiovascular risk factor screening in systemic lupus erythematosus. J. Rheumatol.30, 493–496 (2003).
   PubMed Web of Science ®Google Scholar
• Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract. Res. Clin. Rheumatol.19, 823–838 (2005).
   PubMedGoogle Scholar